我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

OCT评估可降解聚合物DES术后血管修复研究进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第6期
页码:
717-720
栏目:
综述
出版日期:
2017-06-01

文章信息/Info

Title:
Research advances in optical coherence tomography-based vascular healing evaluation after biodegradable polymer drug-eluting stents implantation
作者:
朱永翔; 潘道蓉; 朱 灏; 蔡金赞; 张瑶俊
(南京医科大学附属南京医院（南京市第一医院）心血管内科，江苏 南京 210006)
Author(s):
ZHU Yong-xiang;  PAN Dao-rong;  ZHU Hao;  CAI Jin-zan;  ZHANG Yao-jun
(Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China)
关键词:
可降解聚合物药物洗脱支架; 血管再内皮化; 血管修复; 光学相干断层成像
Keywords:
biodegradable polymer drug-eluting stents;  re-endothelialization;  vascular healing;  optical coherence tomography
分类号:
R618
DOI:
-
文献标识码:
A
摘要:
与裸金属支架相比，第1代药物洗脱支架（drug-eluting stent，DES）显著提高了治疗的有效性，但其永久聚合物涂层使得支架植入后内皮化延迟、血管修复受损，导致晚期支架内血栓的发生率明显升高。在此基础上新一代DES应运而生，可降解聚合物DES作为其典型代表，通过优化设计等明显改善了其植入后血管修复的进程。光学相干断层成像（OCT）作为目前分辨率最高的血管腔内影像学技术，可用于评估支架植入后内皮覆盖程度，判断血管修复情况，预测血栓性事件发生风险。本文将主要对OCT评估可降解聚合物DES植入术后血管修复及再内皮化做一综述。
Abstract:
Drug-eluting stents (DES) significantly improved the clinical efficiency in treating patients with coronary artery disease compared with bare metal stents. However, durable polymers of DES will prolong re-endothelialization and impair vascular healing, which will result in an increased risk of late stent thrombosis. Recently, newer generation stents (e.g. biodegradable polymer DES) have been designed to overcome these drawbacks. The optimization of stent components has improved vascular healing after DES implantation. Optical coherence tomography, an intravascular imaging modality, with its high resolution can be used to evaluate re-endothelilization and vascular healing after DES implantation, which provides the possibility of predicting risk of thrombotic events. The present review aims to summarize the research progress with respect to vascular healing and re-endothelialization after biodegradable polymer DES implantation.

参考文献/References

[1]Parodi G,La Manna A,Di VL,et al.Stent-related defects in patients presenting with stent thrombosis:differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST)study[J].EuroIntervention,2013,9(8):936-944.
[2]Kim BK,Hong MK,Shin DH,et al.Optical coherence tomography analysis of strut coverage in biolimus- and sirolimus-eluting stents:3-month and 12-month serial follow-up[J].Int J Cardiol,2013,168(5):4617-4623.
[3]Barlis P,Regar E,Serruys PW,et al.An optical coherence tomography study of a biodegradable vs.durable polymer-coated limus-eluting stent:a LEADERS trial sub-study[J].Eur Heart J,2010,31(2):165-176.
[4]Staico R,Costa Ma,Chamié D,et al.Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography[J].Int J Cardiovasc Imaging,2013,29(5):977-988.
[5]Christiansen EH,Jensen LO,Thayssen P,et al.Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention(SORT OUT V):a randomised non-inferiority trial[J].Lancet,2013,381(9867):661-669.
[6]Palmerini T,Biondi-Zoccai G,Della RD,et al.Clinical outcomes with bioabsorbable polymer-versus durable polymer-based drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis[J].J Am Coll Cardiol,2014,63(4):299-307.
[7]Davlouros PA,Mavronasiou E,Xanthopoulou I,et al.An optical coherence tomography study of two new generation stents with biodegradable polymer carrier,eluting paclitaxel vs.biolimus-A9[J].Int J Cardiol,2012,157(3):341-346.
[8]Kubo T,Akasaka T,Kozuma K,et al.Vascular response to drug-eluting stent with biodegradable vs.durable polymer.Optical coherence tomography substudy of the NEXT[J].Circ J,2014,78(10):2408-2414.
[9]Konishi A,Shinke T,Otake H,et al.Favorable vessel healing after nobori biolimus A9-eluting stent implantation-6- and 12-month follow-up by optical coherence tomography[J].Circ J,2014,78(8):1882-1890.
[10]Hamon M,Niculescu R,Deleanu D,et al.Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions(BIOFLOW-I):a prospective,first-in-man study[J].EuroIntervention,2013,8(9):1006-1011.
[11]Pilgrim T,Heg D,Roffi M,et al.Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation(BIOSCIENCE):a randomised, single-blind,non-inferiority trial[J].Lancet,2014,384(9960):2111-2122.
[12]Windecker S,Haude M,Neumann FJ,et al.Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent:results of the randomized BIOFLOW-II trial[J].Circ Cardiovasc Interv,2015,8(2):e001441.
[13]Karjalainen PP,Varho V,Nammas W,et al.Early neointimal coverage and vasodilator response following biodegradable polymer sirolimus-eluting vs. durable polymer zotarolimus-eluting stents in patients with acute coronary syndrome -HATTRICK-OCT trial[J].Circ J,2015,79(2):360-367.
[14]Attizzani GF,Bezerra HG,Chamie D,et al.Serial Evaluation of Vascular Response After Implantation of a New Sirolimus-Eluting Stent With Bioabsorbable Polymer(MISTENT):Lan optical coherence tomography and histopathological study[J].J Invasive Cardiol,2012,24(11):560-568.
[15]Attizzani GF,Bezerra HG,Ormiston J,et al.Serial assessment by optical coherence tomography of early and late vascular responses after implantation of an absorbable-coating Sirolimus-Eluting stent(from the first-in-human DESSOLVE I trial)[J].Am J Cardiol,2013,112(10):1557-1564.
[16]Ormiston J,Webster M,Stewart J,et al.First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent:imaging and clinical results of the DESSOLVE I Trial(DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries)[J].JACC Cardiovasc Interv, 2013,6(10):1026-1034.
[17]Rusinaru D,Vrolix M,Verheye S,et al.Bioabsorbable polymer-coated sirolimus-eluting stent implantation preserves coronary vasomotion:A DESSOLVE II trial sub-study[J].Catheter Cardiovasc Interv, 2015,86(7):1141-1150.
[18]Wijns W,Vrolix M,Verheye S,et al.Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent:results of the DESSOLVE II trial[J].EuroIntervention,2015,10(12):1383-1390.
[19]潘道蓉,朱 灏,庞 思,等.OCT评估国产可降解聚合物药物洗脱支架术后血管修复研究进展[J].临床军医杂志,2016,(5):539-541.
[20]Pan DR,Zhu H,Hu ZY,et al.Cobalt chromium-based biodegradable polymer sirolimus-eluting stent: rationale, evidence and clinical experience[J].Minerva Cardioangiol,2015,63(5):411-426.
[21]Meredith IT,Verheye S,Dubois CL,et al.Primary endpoint results of the EVOLVE trial:a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent[J].J Am Coll Cardiol,2012,59(15):1362-1370.
[22]Meredith IT,Verheye S,Weissman NJ,et al.Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated,everolimus-eluting stent[J].EuroIntervention,2013,9(3):308-315.

备注/Memo

备注/Memo:
收稿日期: 2016-08-12.基金项目：南京市医学科技发展资金项目资助（YKK15100）；南京市科技计划项目资助（201503024）
通讯作者：张瑶俊，副教授，主要从事冠心病研究 Email：13770668667@139.com
作者简介：朱永翔，本科生 Email:zhuyongxiang_njmu@163.com
更新日期/Last Update: 2017-06-06